These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia. Chin CK; Leslie C; Grove CS; Van Vliet C; Cheah CY Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937595 [TBL] [Abstract][Full Text] [Related]
24. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405 [TBL] [Abstract][Full Text] [Related]
25. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930 [No Abstract] [Full Text] [Related]
27. Significances of MYD88 Meng Q; Cao XX; Li J Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839 [TBL] [Abstract][Full Text] [Related]
28. Current options to manage Waldenström's macroglobulinemia. Benevolo G; Nicolosi M; Santambrogio E; Vitolo U Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170 [TBL] [Abstract][Full Text] [Related]
29. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Ghobrial IM; Siegel DS; Vij R; Berdeja JG; Richardson PG; Neuwirth R; Patel CG; Zohren F; Wolf JL Am J Hematol; 2016 Jun; 91(4):400-5. PubMed ID: 26800393 [TBL] [Abstract][Full Text] [Related]
30. [New developments in Waldenström's macroglobulinemia]. Grunenberg A; Buske C Dtsch Med Wochenschr; 2016 Feb; 141(3):170-2. PubMed ID: 26841176 [TBL] [Abstract][Full Text] [Related]
31. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
32. Clinical application of genomics in Waldenström macroglobulinemia. Branagan AR; Lei M; Treon SP; Castillo JJ Leuk Lymphoma; 2021 Aug; 62(8):1805-1815. PubMed ID: 33569985 [TBL] [Abstract][Full Text] [Related]
33. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia. Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Shiibashi R; Izutsu K Cancer Sci; 2020 Sep; 111(9):3327-3337. PubMed ID: 32639651 [TBL] [Abstract][Full Text] [Related]
34. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions. Thomas SK Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578 [TBL] [Abstract][Full Text] [Related]
35. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995 [TBL] [Abstract][Full Text] [Related]